|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
US4515894A
(en)
|
1979-03-20 |
1985-05-07 |
Ortho Pharmaceutical Corporation |
Hybrid cell line for producing monoclonal antibody to human T cells
|
|
US4363799A
(en)
|
1979-03-20 |
1982-12-14 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to human T cells, and methods for preparing same
|
|
US4657760A
(en)
|
1979-03-20 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Methods and compositions using monoclonal antibody to human T cells
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
US4675386A
(en)
|
1979-11-27 |
1987-06-23 |
Regents Of The University Of California |
Monoclonal antibody methods and compositions specific for single antigens in antigen aggregates
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
ATE114723T1
(de)
|
1987-03-02 |
1994-12-15 |
Enzon Lab Inc |
Organismus als träger für ''single chain antibody domain (scad)''.
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
EP0397798A4
(en)
|
1988-02-03 |
1991-10-30 |
Xoma Corporation |
Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
|
|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
JP2938569B2
(ja)
|
1990-08-29 |
1999-08-23 |
ジェンファーム インターナショナル，インコーポレイティド |
異種免疫グロブリンを作る方法及びトランスジェニックマウス
|
|
IT1249051B
(it)
*
|
1991-02-26 |
1995-02-11 |
Italfarmaco Spa |
Immunotossina da anticorpi monoclonali anti-cd5
|
|
EP0503646A1
(en)
|
1991-03-12 |
1992-09-16 |
Biogen, Inc. |
Monoclonal antibodies recognizing lymphocyte function associated antigen-3
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
JP3951062B2
(ja)
|
1991-09-19 |
2007-08-01 |
ジェネンテック・インコーポレーテッド |
少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
|
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6162432A
(en)
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US5837491A
(en)
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
WO1993011794A1
(en)
|
1991-12-13 |
1993-06-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
DE69231123T2
(de)
|
1992-03-25 |
2001-02-15 |
Immunogen Inc |
Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US7592006B1
(en)
|
1993-03-05 |
2009-09-22 |
Université Catholique de Louvain |
Composition comprising the LO-CD2a antibody
|
|
US5817311A
(en)
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
|
US5951983A
(en)
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
|
US5730979A
(en)
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
ES2164699T3
(es)
|
1993-03-05 |
2002-03-01 |
Univ Catholique Louvain |
Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.
|
|
DE4312916C2
(de)
|
1993-04-14 |
1995-03-23 |
Fresenius Ag |
Arzneimittel zur Behandlung von Immunreaktionen
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5795572A
(en)
|
1993-05-25 |
1998-08-18 |
Bristol-Myers Squibb Company |
Monoclonal antibodies and FV specific for CD2 antigen
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
DE69519513T2
(de)
|
1994-03-08 |
2001-07-19 |
Dana-Farber Cancer Institute, Boston |
Verfahren zur modulation von "t-zell-anergy"
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
AU5981796A
(en)
|
1995-06-07 |
1997-01-09 |
Thera Pro |
Pyrularia thionin containing immunotoxins and immunotoxin-li ke conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
DE69626849T2
(de)
|
1995-12-22 |
2003-12-24 |
Bristol-Myers Squibb Co., Princeton |
Verzweigte hydrazongruppen enthaltende kuppler
|
|
US6218519B1
(en)
|
1996-04-12 |
2001-04-17 |
Pro-Neuron, Inc. |
Compounds and methods for the selective treatment of cancer and bacterial infections
|
|
WO1998010055A1
(en)
|
1996-09-03 |
1998-03-12 |
Kaneka Corporation |
Method for inducing immunosuppressive cells and culturing device to be used therefor
|
|
CA2264227A1
(en)
|
1996-09-27 |
1998-04-02 |
Raymond A. Firestone |
Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
|
ES2301183T3
(es)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
Anticuerpo completamente humano que se une al receptor del egfr.
|
|
US6849258B1
(en)
|
1997-07-18 |
2005-02-01 |
Universite Catholique De Louvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
US6358506B1
(en)
|
1997-11-05 |
2002-03-19 |
University Of Southern California |
Use of cytokines and mitogens to inhibit pathological immune responses
|
|
JP2001523645A
(ja)
|
1997-11-14 |
2001-11-27 |
ザ・ゼネラル・ホスピタル・コーポレイション |
血液学的疾患の処置
|
|
US20060051355A1
(en)
|
1998-03-23 |
2006-03-09 |
Van Oosterhout Ypke V |
Methods and means for the treatment of immune-related diseases
|
|
EA003398B1
(ru)
|
1998-05-22 |
2003-04-24 |
Дайити Фармасьютикал Ко., Лтд. |
Лекарственный комплекс c полимерным носителем
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
AU2980900A
(en)
|
1999-02-04 |
2000-08-25 |
General Hospital Corporation, The |
Methods for human allografting
|
|
US6268488B1
(en)
|
1999-05-25 |
2001-07-31 |
Barbas, Iii Carlos F. |
Prodrug activation using catalytic antibodies
|
|
US6541611B1
(en)
|
1999-06-18 |
2003-04-01 |
Universite Catholique De Louvain |
LO-CD2b antibody
|
|
US20040052793A1
(en)
|
2001-02-22 |
2004-03-18 |
Carter Paul J. |
Caspase activivated prodrugs therapy
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
AU2002250236A1
(en)
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
US20040265315A1
(en)
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
DK1664122T3
(da)
|
2003-09-18 |
2010-06-28 |
Novartis Ag |
Terapeutisk humaniserede antistoffer mod CD45-isoformer
|
|
CN104998273A
(zh)
|
2003-11-06 |
2015-10-28 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
AU2005216251B2
(en)
|
2004-02-23 |
2011-03-10 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
EP3088004B1
(en)
|
2004-09-23 |
2018-03-28 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
EP1661584A1
(en)
|
2004-11-26 |
2006-05-31 |
Heinz Dr. Faulstich |
Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
|
|
EP1859811B1
(en)
|
2006-05-27 |
2011-08-24 |
Faulstich, Heinz, Dr. |
Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
|
|
WO2008067115A2
(en)
|
2006-11-03 |
2008-06-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Selective immunodepletion of endogenous stem cell niche for engraftment
|
|
WO2008121160A2
(en)
*
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
|
ITBO20070242A1
(it)
|
2007-04-03 |
2008-10-04 |
Gsg Int Spa |
Profilato per serramenti scorrevoli, metodo per la realizzazione del profilato, e serramento ottenuto con il profilato stesso.
|
|
CN104524592B
(zh)
|
2008-04-30 |
2018-06-05 |
伊缪诺金公司 |
交联剂和它们的用途
|
|
CN102137873A
(zh)
|
2008-08-29 |
2011-07-27 |
西福根有限公司 |
抗cd5抗体
|
|
JP2012523383A
(ja)
|
2009-04-08 |
2012-10-04 |
ファウルシュティヒ，ハインツ |
がんの治療のためのアマトキシンと複合体形成した標的結合部分
|
|
EP3485912A1
(en)
|
2009-04-08 |
2019-05-22 |
Faulstich, Heinz, Dr. |
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
|
|
PT2430051T
(pt)
|
2009-05-14 |
2016-07-11 |
Inst Nat De La Santé Et De La Rech Medicale |
Composições contendo anticorpos para tratar doenças relacionadas com células b ou t cd5+ hla- dr+
|
|
RU2645069C2
(ru)
*
|
2010-08-18 |
2018-02-15 |
Авм Байотекнолоджи, Ллс |
Композиции и способы для ингибирования связывания стволовых клеток и клеток-предшественников с лимфоидной тканью и для регенерации зародышевых центров в лимфатических тканях
|
|
CN103270050A
(zh)
|
2010-09-08 |
2013-08-28 |
耶达研究及发展有限公司 |
用于稳定和长期移植的免疫抑制药物组合
|
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
|
EP2497499A1
(en)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Amatoxin-conjugates with improved linkages
|
|
ES2811529T3
(es)
|
2011-12-22 |
2021-03-12 |
Yeda Res & Dev |
Una terapia de combinación para un injerto estable y a largo plazo usando protocolos específicos para el agotamiento de los linfocitos T/B
|
|
WO2013116307A1
(en)
*
|
2012-01-30 |
2013-08-08 |
Mount Sinai School Of Medicine |
Method for programming differentiated cells into hematopoietic stem cells
|
|
US20130280282A1
(en)
|
2012-04-24 |
2013-10-24 |
Daiichi Sankyo Co., Ltd. |
Dr5 ligand drug conjugates
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
EP2684865A1
(en)
|
2012-07-13 |
2014-01-15 |
Heidelberg Pharma GmbH |
Methods for synthesizing amatoxin building block and amatoxins
|
|
WO2014043403A1
(en)
|
2012-09-12 |
2014-03-20 |
Agensys, Inc. |
Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
|
|
CA2888445A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Methods for making conjugates from disulfide-containing proteins
|
|
CN105431521A
(zh)
|
2013-02-28 |
2016-03-23 |
哈佛学院校长同事会 |
用于动员干细胞的方法和组合物
|
|
EP2774624A1
(en)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Amatoxin derivatives
|
|
EP2968591A1
(en)
|
2013-03-15 |
2016-01-20 |
Novartis AG |
Cell proliferation inhibitors and conjugates thereof
|
|
US11116847B2
(en)
|
2013-12-19 |
2021-09-14 |
Seagen Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
|
EP3145542A4
(en)
|
2014-05-20 |
2018-01-17 |
ImmunoGen, Inc. |
Methods for characterizing and treating acute myeloid leukemia
|
|
CN107106701B
(zh)
|
2014-10-03 |
2020-11-06 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
WO2016071856A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
|
SI3268047T1
(sl)
*
|
2015-03-09 |
2024-02-29 |
Heidelberg Pharma Research Gmbh |
Konjugati amatoksin-protitelo
|
|
WO2016164502A1
(en)
|
2015-04-06 |
2016-10-13 |
President And Fellows Of Harvard College |
Compositions and methods for non-myeloablative conditioning
|
|
EP3286225B1
(en)
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Cd5 chimeric antigen receptor for adoptive t cell therapy
|
|
KR20240063203A
(ko)
|
2015-06-29 |
2024-05-09 |
이뮤노젠 아이엔씨 |
항-cd123 항체 및 이들의 접합체와 유도체
|
|
US20170129128A1
(en)
|
2015-11-05 |
2017-05-11 |
Black & Decker Inc. |
Saw
|
|
AU2016360828B2
(en)
|
2015-11-27 |
2021-06-24 |
Heidelberg Pharma Research Gmbh |
Derivatives of gamma-amanitin
|
|
EP3222292A1
(en)
|
2016-03-03 |
2017-09-27 |
Heidelberg Pharma GmbH |
Amanitin conjugates
|
|
MY197235A
(en)
|
2016-04-20 |
2023-06-07 |
Hangzhou Dac Biotech Co Ltd |
Derivatives of amanita toxins and their conjugation to a cell binding molecule
|
|
WO2017191579A1
(en)
|
2016-05-05 |
2017-11-09 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
|
CN109661400A
(zh)
|
2016-06-17 |
2019-04-19 |
美真达治疗公司 |
用于耗尽cd117+细胞的组合物和方法
|
|
SG11201811292RA
(en)
|
2016-06-17 |
2019-01-30 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cells
|
|
WO2018115466A1
(en)
|
2016-12-23 |
2018-06-28 |
Heidelberg Pharma Research Gmbh |
Amanitin antibody conjugates
|
|
CN110461876B
(zh)
|
2017-01-20 |
2024-05-17 |
海德堡医药研究有限责任公司 |
用于耗尽cd137+细胞的组合物和方法
|
|
EP3630980B1
(en)
|
2017-06-01 |
2023-11-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
CN110997676B
(zh)
|
2017-08-07 |
2022-12-20 |
海德堡医药研究有限责任公司 |
合成鹅膏蕈碱的新方法
|
|
WO2019084064A2
(en)
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
|
|
IL316155A
(en)
|
2017-11-29 |
2024-12-01 |
Heidelberg Pharma Res |
Compositions and Methods for the Depletion of CD5(PLUS) CELLS
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
AU2019311077B2
(en)
|
2018-07-23 |
2025-05-29 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|